Independence Blue Cross (Independence) hosted The American Cancer Society Cancer Action Network’s forum today to discuss and highlight advancements in cancer research through immunotherapy.
The event focused on the progress researchers are making in immunotherapy, which is treatment that uses the body’s own immune system to help fight cancer. The discussion also included the important role that federal funding has in fueling cancer research.
Nearly 50 key stakeholders from throughout the oncology community attended, including leaders in business, academia, public policy, patient advocacy, and physician groups. Dr. Don Liss, vice president of Clinical Programs and Policy for Independence, moderated a panel discussion with three leading cancer experts from Fox Chase Cancer Center, the University of Pennsylvania, and Thomas Jefferson University Hospital.
In January, Independence became the first major insurer to offer coverage for next-generation whole genome sequencing. This single test fully sequences thousands of genes, detecting DNA mutations that may serve as markers that inform decisions about optimal cancer therapy.